Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for KaloBios Pharmaceuticals Inc. (HGEN : NSDQ)
 
 • Company Description   
Humanigen, Inc. is a biopharmaceutical company. It focuses on advancing medicines for patients with neglected and rare diseases. The Company's product candidate principally consists of benznidazole, lenzilumab and ifabotuzumab. Humanigen Inc., formerly known as KaloBios Pharmaceuticals Inc., is based in Brisbane, United States.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.24 Daily Weekly Monthly
20 Day Moving Average: 1,341,578 shares
Shares Outstanding: 70.63 (millions)
Market Capitalization: $158.22 (millions)
Beta: -1.01
52 Week High: $23.53
52 Week Low: $1.67
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.66% 19.01%
12 Week 13.71% 25.01%
Year To Date -39.78% -26.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
830 Morris Turnpike 4th Floor
-
Short Hills,NJ 07078
USA
ph: 650-243-3100
fax: -
ir@humanigen.com http://www.humanigen.com
 
 • General Corporate Information   
Officers
Cameron Durrant - Chief Executive Officer and Chairman
Timothy Morris - Chief Operating Officer and Chief Financial Office
Ronald Barliant - Director
Rainer Boehm - Director
Cheryl Buxton - Director

Peer Information
KaloBios Pharmaceuticals Inc. (CORR.)
KaloBios Pharmaceuticals Inc. (RSPI)
KaloBios Pharmaceuticals Inc. (CGXP)
KaloBios Pharmaceuticals Inc. (BGEN)
KaloBios Pharmaceuticals Inc. (GTBP)
KaloBios Pharmaceuticals Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 444863203
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 70.63
Most Recent Split Date: 9.00 (0.20:1)
Beta: -1.01
Market Capitalization: $158.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 38.17
EPS Growth
vs. Year Ago Period: 74.40%
vs. Previous Quarter: 39.62%
Sales Growth
vs. Year Ago Period: 113.17%
vs. Previous Quarter: -0.10%
ROE
03/31/22 - -24,421.51
12/31/21 - -4,882.88
09/30/21 - -1,062.54
ROA
03/31/22 - -224.95
12/31/21 - -256.13
09/30/21 - -256.70
Current Ratio
03/31/22 - 1.00
12/31/21 - 1.03
09/30/21 - 1.13
Quick Ratio
03/31/22 - -
12/31/21 - 1.03
09/30/21 - 1.13
Operating Margin
03/31/22 - -4,640.77
12/31/21 - -6,582.73
09/30/21 - -8,202.23
Net Margin
03/31/22 - -4,640.77
12/31/21 - -6,582.73
09/30/21 - -8,202.23
Pre-Tax Margin
03/31/22 - -4,640.77
12/31/21 - -6,582.73
09/30/21 - -8,202.23
Book Value
03/31/22 - -0.35
12/31/21 - -0.37
09/30/21 - -0.30
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©